This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Technical Review: New Releases From Drug Maker Majors Cushion Against Patent Cliff Effects

LONDON, January 16, 2013 /PRNewswire/ --

All companies mentioned in the release below have received technical review as of the close of yesterday's session. These reports are available for free at http://www.stockcall.com/register

For many major drug manufacturers, including Pfizer Inc. (1) (NYSE: PFE ) and Merck & Co. Inc. (2) (NYSE: MRK), the so-called "patent cliff" put a major dent in sales and profits. The loss of exclusivity of many blockbuster drugs allowed generics to be made, and major drug companies have been left to compete with generic versions that are, in most cases, cheaper.

One of the historically best-selling drug which went off-patent in November 2011 is Lipitor. The anti-cholesterol drug was Pfizer's golden goose as it earned the company close to $9.6 billion in revenue in 2011. Merck & Co. also suffered from patent loss with some of its blockbuster drugs such as Singulair, Maxalt, Cozaar/Hyzaar fell off the patent cliff. But these companies have learnt to survive. Register with us today and access the technical report in Merck & Co. at

http://www.StockCall.com/MRK011613.pdf

While several brand-name drug companies have come out with their own generic equivalents, sales have still suffered. Successful marketing abroad has also helped to boost sales for select companies; however; numbers are still down from exclusivity highs. Depressed sales for some could be set to rebound though, as companies are succeeding in bringing a slew of exciting, new products to market.

A number of major drug manufacturers are currently focusing their attention on and receiving FDA or European Commission approval, which if granted creates the potential for big returns. Pfizer recently announced that the European Commission gave its approval to expand the company's pneumococcal conjugate vaccine, Prevenar 13 to children and adolescents between the ages of 6 to 17 years. The vaccine is for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type  Streptococcus pneumoniae.

Additionally, industry players are developing treatments and diagnostic methods for a number of conditions, including cancer, Pneumonia, cardiovascular diseases and Alzheimer's among others. With a number of these products newly on the market, it will be interesting to see which, if any, become the next big bread winners for major drug manufacturers.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs